Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

20182,608 citationsJournal Articlebronze Open Access

Authors

Matthew J. Maurer · Columbia University

Jeffrey H. Schwartz · Pfizer (United States)

Balarama Gundapaneni · Syneos Health (United States)

Perry Elliott · St Bartholomew's Hospital

Giampaolo Merlini · University of Pavia

Márcia Waddington‐Cruz

Arnt V. Kristen · Heidelberg University

Abstract

In patients with transthyretin amyloid cardiomyopathy, tafamidis was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations and reduced the decline in functional capacity and quality of life as compared with placebo. (Funded by Pfizer; ATTR-ACT ClinicalTrials.gov number, NCT01994889 .).

Topics & Keywords

Amyloidosis: Diagnosis, Treatment, Outcomes Pneumocystis jirovecii pneumonia detection and treatment Medical Imaging and Pathology Studies

Publication Details

Published in: New England Journal of Medicine

Volume 379, Issue 11, pp. 1007-1016

DOI: 10.1056/nejmoa1805689

Field-Weighted Citation Impact: 86.98

Command Palette

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Authors

Abstract

Topics & Keywords

Publication Details